Fatty liver index in polycystic ovary syndrome

European Journal of Endocrinology

Volumn 165, Issue 6, 2011, Pages 935-943

  Lerchbaum, Elisabeth ^a   Gruber, Hans Jürgen ^a   Schwetz, Verena ^a   Giuliani, Albrecht ^a   Möller, Reinhard ^a   Pieber, Thomas R ^a   Obermayer Pietsch, Barbara ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; BODY MASS; CONTROLLED STUDY; FATTY LIVER INDEX; FEMALE; FIB 4 INDEX; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; METABOLIC SYNDROME X; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; BODY MASS INDEX; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; TRIGLYCERIDES; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 81555203008     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0614     Document Type: Article

References (43)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED & Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. Journal of Clinical Endocrinology and Metabolism 1999 84 4006-4011. (doi:10.1210/jc.84. 11. 4006)
2. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S & Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. Journal of Clinical Endocrinology and Metabolism 2000 85 2434-2438. (doi:10.1210/jc.85.7. 2434)
3. Azziz R,Woods KS, Reyna R, Key TJ, Knochenhauer ES & Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. Journal of Clinical Endocrinology and Metabolism 2004 89 2745-2749. (doi:10.1210/jc.2003- 032046)
4. Ehrmann DA. Polycystic ovary syndrome. New England Journal of Medicine 2005 352 1223-1236. (doi:10.1056/NEJMra041536)
5. Gambineri A, Pelusi C, Vicennati V, Pagotto U & Pasquali R. Obesity and the polycystic ovary syndrome. International Journal of Obesity and Related Metabolic Disorders 2002 26 883-896. (doi:10. 1038/sj.ijo.0801994)
6. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E & Dumesic DA. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Journal of Clinical Endocrinology and Metabolism 2010 95 2038-2049. (doi:10.1210/jc.2009-2724)
7. Utzschneider KM & Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. Journal of Clinical Endocrinology and Metabolism 2006 91 4753-4761. (doi:10.1210/jc.2006- 0587)
8. Collantes RS, Ong JP & Younossi ZM. The metabolic syndrome and nonalcoholic fatty liver disease. Panminerva Medica 2006 48 41-48. (Pubitemid 43875421)
9. Baranova A, Tran TP, Birerdinc A & Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2011 33 801-814. (doi:10.1111/j. 1365-2036.2011.04579.x)
10. Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E & Tzavara I. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Human Reproduction 2010 25 212-220. (doi:10.1093/humrep/dep380)
11. Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M & Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Annals of Hepatology 2010 9 402-409.
12. Bedogni G, Kahn HS, Bellentani S & Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterology 2010 10 98. (doi:10.1186/1471-230X-10-98)
13. Zawadzki JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach, pp 377-384. Cambridge, MA: Blackwell Scientific, 1992.
14. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS & Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003 38 518-526. (doi:10.1053/jhep. 2003.50346)
15. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M & APRICOT Clinical Investigators . Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006 43 1317-1325. (doi:10.1002/hep.21178)
16. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008 31 (Suppl 1) S12-S54.
17. National Cholesterol Education Program (NCEP) Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002 106 3143-3421.
18. Legro RS, Castracane VD & Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstetrical & Gynecological Survey 2004 59 141-154. (doi:10. 1097/01.OGX.0000109523.25076.E2)
19. Tafeit E, Möller R, Pieber TR, Sudi K & Reibnegger G. Differences of subcutaneous adipose tissue topography in type-2 diabetic (NIDDM) women and healthy controls. American Journal of Physical Anthropology 2000 113 381-388. (doi:10.1002/1096- 8644(200011)113:3〈381::AID-AJPA8〉3.0.CO;2- T)
20. Moeller R, Horejsi R, Pilz S, Lang N, Sargsyan K, Dimitrova R, Tafeit E, Giuliani A, Almer G & Mangge H. Evaluation of risk profiles by subcutaneous adipose tissue topography in obese juveniles. Obesity 2007 15 1319-1324. (doi:10.1038/ oby.2007.154)
21. Jürimäe TSK, Jürimäe J, Payerl D, Möller R & Tafeit E. Validity of optical device lipometer and bioelectric impedance analysis for body fat assessment in men and women. Collegium Antropologicum 2005 29 499-502. (Pubitemid 43111088)
22. Möller R, Tafeit E, Pieber TR, Sudi K & Reibnegger G. Measurement of subcutaneous adipose tissue topography (SAT-Top) by means of a new optical device, lipometer, and the evaluation of standard factor coefficients in healthy subjects. American Journal of Human Biology 2000 12 231-239. (doi:10.1002/(SICI)1520- 6300(200003/04)12:2〈231::AID- AJHB9〉3.0.CO;2-X)
23. Jürimäe T, Jürimäe J, Wallner SJ, Lipp RW, Schnedl WJ, Möller R & Tafeit E. Relationships between body fat measured by DXA and subcutaneous adipose tissue thickness measured by lipometer in adults. Journal of Physiological Anthropology 2007 26 513-516. (doi:10.2114/jpa2.26.513)
24. Möller R, Tafeit E, Smolle KH, Pieber TR, Ipsiroglu O, Duesse M, Huemer C, Sudi K & Reibnegger G. Estimating percentage total body fat and determining subcutaneous adipose tissue distribution with a new noninvasive optical device LIPOMETER. American Journal of Human Biology 2000 12 221-230. (doi:10. 1002/(SICI)1520-6300(200003/04)12:2〈221::AID-AJHB8〉3.0.CO;2- 2)
25. Youden WJ. Index for rating diagnostic tests. Cancer 1950 3 32-35. (doi:10.1002/1097-0142(1950)3:1〈32::AID-CNCR282 0030106〉3.0.CO;2-3)
26. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B & RISC Investigators . Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009 49 1537-1544. (doi:10.1002/hep. 22845)
27. Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L & Perseghin G. Fatty liver index (FLI) and mortality: the Cremona study at the 15(th) year of follow up. Hepatology 2011 54 145-152. (doi:10.1002/hep. 24356)
28. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S, Cavallo MG, Zalunardo B, Lirussi F, Alessandri C & Violi F. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. Journal of Clinical Endocrinology and Metabolism 2005 90 1578-1582. (doi:10.1210/jc.2004-1024)
29. Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008 51 1781-1789. (doi:10. 1007/s00125-008-1116-7)
30. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C & Tataranni PA. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002 51 1889-1895. (doi:10.2337/diabetes.51.6.1889)
31. Targher G, Day CP & Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New England Journal of Medicine 2010 363 1341-1350. (doi:10.1056/ NEJMra0912063)
32. Wehr E, Gruber HJ, Giuliani A, Möller A, Pieber TR & Obermayer-Pietsch B. The lipid accumulation product is associated with impaired glucose tolerance in PCOS women. Journal of Clinical Endocrinology and Metabolism 2011 96 E986-E990. (doi:10.1210/jc.2011-0031)
33. Ma RC, Liu KH, Lam PM, Cheung LP, Tam WH, Ko GT, Chan MH, Ho CS, Lam CW, Chu WC, Tong PC, So WY, Chan JC & Chow CC. Sonographic measurement of mesenteric fat predicts presence of fatty liver among subjects with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2010 96 799-807. (doi:10.1210/jc.2010-1608)
34. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM & Brown AJ. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2006 91 1741-1747. (doi:10.1210/jc.2005-2774)
35. Schwimmer JB, Khorram O, Chiu V & Schwimmer WB. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertility and Sterility 2005 83 494-497. (doi:10. 1016/j.fertnstert.2004.08.020)
36. Economou F, Xyrafis X, Livadas S, Androulakis II, Argyrakopoulou G, Christakou CD, Kandaraki E, Palioura E & Diamanti-Kandarakis E. In overweight/obese but not in normalweight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones 2009 8 199-206.
37. Cerda C, Pérez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, Espinoza M, Pizarro M, Solis N, Miquel JF & Arrese M. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Journal of Hepatology 2007 47 412-417. (doi:10.1016/j.jhep.2007.04.012)
38. Tan S, Bechmann LP, Benson S, Dietz T, Eichner S, Hahn S, Janssen OE, Lahner H, Gerken G, Mann K & Canbay A. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2010 95 343-348. (doi:10.1210/jc.2009-1834)
39. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC & Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clinical Gastroenterology and Hepatology 2007 5 496-501. (doi:10.1016/ j.cgh.2006.10.010)
40. Younossi ZM. Nonalcoholic fatty liver disease. Current Gastroenterology Reports 1999 1 57-62. (doi:10.1007/s11894- 999-0088-1)
41. Méndez-Sánchez N, Arrese M, Zamora-Valdés D & Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver International 2007 27 423-433. (doi:10.1111/j. 1478-3231.2007.01483.x)
42. Caldwell SH, Lee VD, Kleiner DE, Al-Osaimi AM, Argo CK, Northup PG & Berg CL. NASH and cryptogenic cirrhosis: a histological analysis. Annals of Hepatology 2009 8 346-352.
43. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ & Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG : an International Journal of Obstetrics and Gynaecology 2006 113 1210-1217. (doi:10.1111/j.1471- 0528.2006.01008.x)